Rates of multiple sclerosis relapse decrease during pregnancy but increase postpartum.
The rate and frequency of relapse vary for patients with multiple sclerosis, and many report not visiting a health care provider during relapse.
From September 2010 to February 2018, the FDA has identified 35 cases of severe increased disability accompanied by the presence of new lesions on MRI that occurred 2 to 24 weeks after stopping treatment with fingolimod.
According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.
Pediatric MS is predominantly inflammatory in nature, with a presentation that is similar to a number of other conditions.
A nationwide epidemiologic study in France examined a correlation between Guillain-Barré syndrome and recent bone or digestive organ surgery.
Nusinersen, an antisense oligonucleotide that increases functional SMN protein production from SMN2, was clinically effective for improving motor function.
Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.
Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.
Cannabinoids may be mildly effective at treating spasticity, pain, and bladder dysfunction in adults with multiple sclerosis.
Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trialOctober 17, 2018
Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.
All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.
Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.
Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.
Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.
Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.
Disability progression is slower among patients with pediatric-onset multiple sclerosis.
In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.
Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.
Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.
Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.
The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.
Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.
Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).
Participants showed a significant decrease in annual relapse rate and a significant improvement in both patient-reported disability scores and information processing scores.
Researchers pooled long-term data on the safety of cladribine tablets monotherapy that extended 3 or more years beyond the data included in the last clinical study.
Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.
Researchers analyze the dietary habits of 260 patients in the early stages of multiple sclerosis from baseline to 5 years after initial onset of symptoms.
Reserachers evaluated data from the CLARITY study to test the efficacy of cladribine tablets on frequency and severity of relapses for patients with multiple sclerosis.
Neurology Advisor Articles
- Surgical, Nonsurgical Treatments for Chronic Migraine: Evidence and Relevancy
- Neurofilament Light Biomarkers Identify Alzheimer Disease Risk in Down Syndrome
- Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis
- Tap Water in Neti Pot Linked to Brain Infection, Death From Balamuthia mandrillaris
- Rituximab Effects in Neuromyelitis Optica Spectrum Disorders
- Study Identifies Early-Onset Motor Behaviors in DES-Triggered Seizures
- Autoimmune Diseases Increase Hippocampal Sclerosis Risk in Nonagenarians
- Smaller Heads Related to Opioid-Related Neonatal Abstinence Syndrome
- Hearing Loss in Older Adults Linked to Depression, Dementia Among Other Comorbidities
- Bumetanide May Benefit Children With Autism Spectrum Disorder